Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China · Delayed Price · Currency is CNY 65.26
+1.75 (2.76%)
Feb 3, 2026, 3:00 PM CST
SHA:688621 Revenue
Beijing Sun-Novo Pharmaceutical Research had revenue of 265.46M CNY in the quarter ending September 30, 2025, a decrease of -24.97%. This brings the company's revenue in the last twelve months to 1.02B, down -12.04% year-over-year. In the year 2024, Beijing Sun-Novo Pharmaceutical Research had annual revenue of 1.08B with 15.70% growth.
Revenue (ttm)
1.02B
Revenue Growth
-12.04%
P/S Ratio
7.01
Revenue / Employee
653.96K
Employees
1,359
Market Cap
7.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.08B | 146.35M | 15.70% |
| Dec 31, 2023 | 932.12M | 255.51M | 37.76% |
| Dec 31, 2022 | 676.61M | 182.96M | 37.06% |
| Dec 31, 2021 | 493.65M | 146.29M | 42.12% |
| Dec 31, 2020 | 347.36M | 113.83M | 48.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HPGC Renmintongtai Pharmaceutical | 10.22B |
| Northeast Pharmaceutical Group | 6.85B |
| Hunan Jiudian Pharmaceutical | 3.05B |
| Shandong Wit Dyne Health | 2.36B |
| HARBIN GLORIA PHARMACEUTICALS Co., LTD | 2.25B |
| Jiuzhitang | 1.94B |
| Zhejiang AngLiKang Pharmaceutical CO.,LTD. | 1.45B |
| Hunan Er-Kang Pharmaceutical | 1.29B |